京新藥業(002020.SZ):擬與控股股東、大股東共同捐贈300萬元發起設立新昌縣京新公益基金會
格隆匯4月1日丨京新藥業(002020.SZ)公佈,2020年3月31日,公司召開第七屆董事會第八次會議,審議通過了《關於共同發起設立公益基金會暨關聯交易的議案》,同意公司與控股股東呂鋼、大股東京新控股集團有限公司(“京新控股”)共同捐贈300萬元人民幣發起設立新昌縣京新公益基金會(“基金會”),其中公司捐贈200萬元,呂鋼捐贈50萬元,京新控股捐贈50萬元。
此次所捐贈項用於扶危濟困、助學興教、公益援助和農村公益建設,是公司積極履行上市公司社會責任、回饋社會的重要表現,有助於提升公司品牌形象和市場聲譽。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.